Form 4: Bristol-Myers Squibb CEO Christopher Boerner Reports Changes in Beneficial Ownership
SEC Form 4
CEO Christopher Boerner reports transactions involving Bristol-Myers Squibb common stock and market share/performance units, including vesting, adjustments, and tax withholdings.
Summary
- Christopher Boerner, CEO of Bristol-Myers Squibb, filed a Form 4 detailing changes in his beneficial ownership of company stock and derivative securities.
- On March 10, 2024, Boerner engaged in multiple transactions involving common stock, market share units, and performance shares.
- These transactions include the vesting of market share units granted in 2020 and 2021, as well as the distribution of performance shares earned under the 2021-2023 Long-Term Performance Award.
- Some market share units granted in 2022 and 2023 were cancelled due to not meeting the minimum payout factor of 80%.
- Shares were also withheld for payment of taxes upon the vesting of awards.
- The reported transactions resulted in adjustments to Boerner's holdings of common stock and derivative securities, leaving him with 101,205 shares of common stock and 148,026 performance shares.
Sentiment
Score: 6
Explanation: The document is a routine filing related to executive compensation. The cancellation of some market share units is a minor negative, but overall the sentiment is neutral.
Negatives
- Cancellation of market share units granted in 2022 and 2023 due to not meeting the minimum payout factor of 80%.
Industry Context
Executive compensation and stock ownership are closely monitored in the pharmaceutical industry to align management interests with shareholder value.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include a mix of salary, stock options, restricted stock units, and performance-based bonuses.
- Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar long-term incentive plans to motivate executives and reward performance.
- The vesting schedules and performance metrics used in Bristol-Myers Squibb's equity awards are generally consistent with industry practices.
Stakeholder Impact
- The reported transactions have a minor impact on shareholders, as they reflect changes in the CEO's ownership stake.
- The vesting of equity awards incentivizes the CEO to drive long-term value creation for the company.
Key Dates
| Date | Description |
|---|---|
| 03/10/2020 | Grant date of market share units, one-quarter of which vested on 03/10/2024 |
| 03/10/2021 | Grant date of market share units, one-quarter of which vested on 03/10/2024 |
| 03/10/2022 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to the 80% minimum payout factor not being achieved. |
| 03/10/2023 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to the 80% minimum payout factor not being achieved. |
| 03/10/2024 | Date of transactions reported in the Form 4, including vesting of market share units, distribution of performance shares, and tax withholdings. |
| 03/12/2024 | Date of signature on the Form 4 filing. |
| 03/10/2025 | Expiration date of market share units granted on 03/10/2021. |
| 03/10/2026 | Date of market share units granted on 03/10/2022. |
| 03/10/2027 | Date of market share units granted on 03/10/2023 and distribution of performance shares. |
| 03/10/2028 | Date of market share units granted on 03/10/2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.